277 related articles for article (PubMed ID: 15870716)
1. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Awada A; Hendlisz A; Gil T; Bartholomeus S; Mano M; de Valeriola D; Strumberg D; Brendel E; Haase CG; Schwartz B; Piccart M
Br J Cancer; 2005 May; 92(10):1855-61. PubMed ID: 15870716
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
5. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
7. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
[TBL] [Abstract][Full Text] [Related]
9. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
[TBL] [Abstract][Full Text] [Related]
10. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Strumberg D; Awada A; Hirte H; Clark JW; Seeber S; Piccart P; Hofstra E; Voliotis D; Christensen O; Brueckner A; Schwartz B
Eur J Cancer; 2006 Mar; 42(4):548-56. PubMed ID: 16426838
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Hande KR; Hagey A; Berlin J; Cai Y; Meek K; Kobayashi H; Lockhart AC; Medina D; Sosman J; Gordon GB; Rothenberg ML
Clin Cancer Res; 2006 May; 12(9):2834-40. PubMed ID: 16675578
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
Garland LL; Taylor C; Pilkington DL; Cohen JL; Von Hoff DD
Clin Cancer Res; 2006 Sep; 12(17):5182-9. PubMed ID: 16951237
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
17. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Duran I; Hotté SJ; Hirte H; Chen EX; MacLean M; Turner S; Duan L; Pond GR; Lathia C; Walsh S; Wright JJ; Dancey J; Siu LL
Clin Cancer Res; 2007 Aug; 13(16):4849-57. PubMed ID: 17699864
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]